Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone-Reference-Cited by-同舟云学术

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

Published:2023-01 Issue:1 Volume:10 Page:e00955
ISSN:2326-3253
Container-title:ACG Case Reports Journal
language:en
Short-container-title:ACG Case Rep J

Author:

Vuyyuru Sudheer K.¹,Morrow Sarah A.²,Jairath Vipul¹

Affiliation:

1. Department of Medicine, Division of Gastroenterology, Schulich School of Medicine, Western University, London, Ontario, Canada

2. Department of Clinical Neurological Sciences, Schulich School of Medicine, Western University, London, Ontario, Canada

Abstract

ABSTRACT Simultaneous occurrence of multiple sclerosis (MS) and ulcerative colitis (UC) is seldom encountered by clinicians and poses unique challenges. The sphingosine-1-phosphate receptor modulator ozanimod has been recently approved for UC. Ozanimod can be used in such scenarios where it can treat both conditions, reducing the need for multiple targeted therapies. We report the first case of successfully treated multiple sclerosis and UC with ozanimod.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference14 articles.

1. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark;Burisch;Clin Gastroenterol Hepatol,2019

2. Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach;García;Sci Rep,2020

3. Clinical features and genetic risk of demyelination following anti-TNF treatment;Lin;J Crohns Colitis,2020

4. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a;Schott;World J Gastroenterol,2007

5. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis;Tuna;J Crohns Colitis,2011

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S1P-receptor modulator ozanimod for inflammatory diseases treatment. (Review of clinical trials and real-world practice);Dokazatel'naya gastroenterologiya;2023